Christopher J Packard
Overview
Explore the profile of Christopher J Packard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lloyd S, Stott D, de Craen A, Kearney P, Sattar N, Perry I, et al.
PLoS One
. 2013 Sep;
8(9):e72642.
PMID: 24023757
Background: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-controlled trial of pravastatin, demonstrated a 19% reduction in coronary outcomes (p=0.006) after a mean of 3.2...
2.
McConnachie A, Walker A, Robertson M, Marchbank L, Peacock J, Packard C, et al.
Eur Heart J
. 2013 Jul;
35(5):290-8.
PMID: 23839541
Aims: To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial...
3.
Poortvliet R, Ford I, Lloyd S, Sattar N, Mooijaart S, de Craen A, et al.
PLoS One
. 2013 Jan;
7(12):e52438.
PMID: 23285043
Variability in blood pressure predicts cardiovascular disease in young- and middle-aged subjects, but relevant data for older individuals are sparse. We analysed data from the PROspective Study of Pravastatin in...
4.
Shiffman D, Trompet S, Louie J, Rowland C, Catanese J, Iakoubova O, et al.
PLoS One
. 2012 Jun;
7(5):e38240.
PMID: 22666496
Statin therapy reduces the risk of coronary heart disease (CHD), however, the person-to-person variability in response to statin therapy is not well understood. We have investigated the effect of genetic...
5.
Bell S, Cooney J, Packard C, Caslake M, Deighan C
Clin Nephrol
. 2012 May;
77(6):445-53.
PMID: 22595386
Aims: Patients with nephrotic range proteinuria are known to have an increased risk of cardiovascular disease partly due to possessing the atherogenic lipoprotein phenotype. The aim of this study was...
6.
Kofler B, Miles E, Curtis P, Armah C, Tricon S, Grew J, et al.
Atherosclerosis
. 2012 Feb;
221(2):467-70.
PMID: 22365656
Here the impact of APOE genotype on CHD risk in UK adults is reported, along with an analysis of APOE genotype × BMI/age/sex interactions. APOE genotype had a significant impact...
7.
Durrington P, Charlton-Menys V, Packard C, Caslake M, Wang J, Bhatnagar D, et al.
J Clin Lipidol
. 2011 Feb;
2(5):384-90.
PMID: 21291764
Background: Familial hypobetalipoproteinemia (FHBL) is a co-dominant disorder associated with low circulating levels of low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (ApoB). A proband was identified in whom the condition...
8.
Li Y, Sabatine M, Tong C, Ford I, Kirchgessner T, Packard C, et al.
Hum Genet
. 2010 Oct;
129(1):17-23.
PMID: 20886236
A single nucleotide polymorphism (SNP) in KIF6, a member of the KIF9 family of kinesins, is associated with differential coronary event reduction from statin therapy in four randomized controlled trials;...
9.
Stott D, Robertson M, Rumley A, Welsh P, Sattar N, Packard C, et al.
Arterioscler Thromb Vasc Biol
. 2009 Dec;
30(3):605-11.
PMID: 20032290
Objective: To determine whether activation of hemostatic function (thrombosis and fibrinolysis) is associated with cognitive decline in older people. Methods And Results: We studied 5804 people (age, 70-82 years) in...
10.
Bell S, Cooney J, Packard C, Caslake M, Deighan C
Atherosclerosis
. 2009 Jan;
205(1):296-301.
PMID: 19150063
Background: Patients with nephrotic range proteinuria have a marked increase in the risk of cardiovascular disease. Qualitative and quantitative changes in lipids and lipoproteins contribute to this increased risk with...